THC:CBD in Daily Practice: Available Data from UK, Germany and Spain

European Neurology

Volumn 75, Issue 1, 2016, Pages 1-3

  Fernández, Óscar ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Multiple sclerosis spasticity; Patient registry; Safety; THC:CBD oromucosal spray

Indexed keywords

MEDICAL CANNABIS; ORAL SPRAY; PLANT EXTRACT; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

CHEMICALLY INDUCED; COMPLICATION; DEPRESSION; FALLING; GERMANY; HUMAN; MARIJUANA ABUSE; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; ORAL SPRAY; PROSPECTIVE STUDY; REGISTER; RETROSPECTIVE STUDY; SPAIN; SWITZERLAND; TREATMENT OUTCOME; UNITED KINGDOM;

ACCIDENTAL FALLS; DEPRESSION; GERMANY; HUMANS; MARIJUANA ABUSE; MEDICAL MARIJUANA; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; ORAL SPRAYS; PLANT EXTRACTS; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; SPAIN; SWITZERLAND; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 85021308762     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000444234     Document Type: Review

References (6)

1. Sativex Oromucosal Spray: Summary of Product Characteristics. 2015. https://www. medicines. org. uk/emc/medicine/23262 (accessed November 2015).
2. Wright S, Etges T: An observational post approval registry study of patients prescribed Sativex®. Results from clinical practice. Mult Scler 2012; 18:S30.
3. Eltayb A, Etges T, Wright S: An observational post approval registry study of patients prescribed Sativex®. Results from clinical practice. Mult Scler 2013; 19(suppl 1):480.
4. Etges T, Taylor A, Karolia K, Lauder H, Daka B, Wright S: A final report of an observational post-marketing safety registry of patients primarily from the United Kingdom who have been prescribed an oromucosal spray containing 9-tetrahydrocannabinol and cannabidiol (THC:CBD). Mult Scler 2015; 21(suppl 11):610.
5. Oreja-Guevara C: Observational safety study of THC: CBD oromucosal spray (Sativex) in multiple sclerosis patients with spasticity. Clin Exp Pharmacol 2015; 5: 184.
6. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P; Sativex Spasticity Study Group: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex( ®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122-1131.